The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 18 de agosto del 2002
We are currently conducting a study of Tamoxifen in combination with enhanced screening using MRI for women between the ages of 25-45. The purpose of the study is to determine whether Tamoxifen will reduce breast density in women prior to menopause, improving the ability to see changes in the breast as well as possibly lowering breast cancer risk directly. We are currently enrolling high-risk women at sites in Philadelphia, Boston, Detroit, Chicago, and Los Angeles and would like to invite you to participate. Study participants will receive a mammogram and MRI every 6 months for the 2-year study period and will take either Tamoxifen or a placebo (sugar pill) for the first year of the study. All procedures and study medications will be paid for by the study. Participants will also be compensated for their time.
If you would like to discuss the study or if you have any questions, please call toll free 1-888-666-6002 or email: firstname.lastname@example.org.Imprima English
Dec 13, 2013 - Anastrozole reduces the risk of breast cancer by about half with few side effects in postmenopausal women at high risk of developing breast cancer, according to a study presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 10 to 14 in San Antonio. The research was simultaneously published online Dec. 12 in The Lancet.
Apr 21, 2014
Oct 24, 2011